These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27641338)

  • 1. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
    Castagnoli L; Ghedini GC; Koschorke A; Triulzi T; Dugo M; Gasparini P; Casalini P; Palladini A; Iezzi M; Lamolinara A; Lollini PL; Nanni P; Chiodoni C; Tagliabue E; Pupa SM
    Oncogene; 2017 Mar; 36(12):1721-1732. PubMed ID: 27641338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
    Koschorke A; Faraci S; Giani D; Chiodoni C; Iorio E; Canese R; Colombo MP; Lamolinara A; Iezzi M; Ladomery M; Vernieri C; de Braud F; Di Nicola M; Tagliabue E; Castagnoli L; Pupa SM
    Cell Oncol (Dordr); 2019 Dec; 42(6):815-828. PubMed ID: 31376137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The landscape of d16HER2 splice variant expression across HER2-positive cancers.
    Volpi CC; Pietrantonio F; Gloghini A; Fucà G; Giordano S; Corso S; Pruneri G; Antista M; Cremolini C; Fasano E; Saggio S; Faraci S; Di Bartolomeo M; de Braud F; Di Nicola M; Tagliabue E; Pupa SM; Castagnoli L
    Sci Rep; 2019 Mar; 9(1):3545. PubMed ID: 30837627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
    Castagnoli L; Ladomery M; Tagliabue E; Pupa SM
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
    Castagnoli L; Iorio E; Dugo M; Koschorke A; Faraci S; Canese R; Casalini P; Nanni P; Vernieri C; Di Nicola M; Morelli D; Tagliabue E; Pupa SM
    J Cell Physiol; 2019 Feb; 234(2):1768-1779. PubMed ID: 30132876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
    Castagnoli L; Iezzi M; Ghedini GC; Ciravolo V; Marzano G; Lamolinara A; Zappasodi R; Gasparini P; Campiglio M; Amici A; Chiodoni C; Palladini A; Lollini PL; Triulzi T; Menard S; Nanni P; Tagliabue E; Pupa SM
    Cancer Res; 2014 Nov; 74(21):6248-59. PubMed ID: 25164009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer.
    Wada R; Yagihashi S; Naito Z
    Mol Med Rep; 2016 Dec; 14(6):5104-5110. PubMed ID: 27840986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway.
    Barnawi R; Al-Khaldi S; Majed Sleiman G; Sarkar A; Al-Dhfyan A; Al-Mohanna F; Ghebeh H; Al-Alwan M
    Stem Cells; 2016 Dec; 34(12):2799-2813. PubMed ID: 27502039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
    Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness.
    Pupa SM; Ligorio F; Cancila V; Franceschini A; Tripodo C; Vernieri C; Castagnoli L
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
    Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
    Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
    Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
    Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
    Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
    BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Isolation of CD44+/CD24 -/low and side population cells from MDA-MB-453 cells and the analysis of their activation of Wnt and Notch pathway].
    Li X; Ren J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):471-5. PubMed ID: 18931707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER
    Liu Y; Nekulova M; Nenutil R; Horakova I; Appleyard MV; Murray K; Holcakova J; Galoczova M; Quinlan P; Jordan LB; Purdie CA; Vojtesek B; Thompson AM; Coates PJ
    J Pathol Clin Res; 2020 Jan; 6(1):83-93. PubMed ID: 31591823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.
    Castiello L; Sestili P; Schiavoni G; Dattilo R; Monque DM; Ciaffoni F; Iezzi M; Lamolinara A; Sistigu A; Moschella F; Pacca AM; Macchia D; Ferrantini M; Zeuner A; Biffoni M; Proietti E; Belardelli F; Aricò E
    Cancer Immunol Res; 2018 Jun; 6(6):658-670. PubMed ID: 29622580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.
    Majumder M; Xin X; Liu L; Tutunea-Fatan E; Rodriguez-Torres M; Vincent K; Postovit LM; Hess D; Lala PK
    Stem Cells; 2016 Sep; 34(9):2290-305. PubMed ID: 27301070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
    Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.